Clinical trials: Normal Control
Pulmonary Fibrosis, Breast Cancer
Trial of Concurrent Versus Sequential Tamoxifen With Radiotherapy in Breast Cancer Patients
Two hundred and sixty patients with breast cancer will be accrued into the study. After inclusion in the study, all the patients will be randomized into two arms.
- Trial name
- CONSET (NCT00896155)
- Testing
- Tamoxifen, Radiotherapy
- Where
- India
- Volunteers
- 260 people
- Sponsor
- Tata Memorial Hospital
Epidermolysis Bullosa
Study of Effectiveness and Safety of SD-101 in Participants With Epidermolysis Bullosa
The purpose of this study was to assess whether the topical use of SD-101 cream (3% or 6%) was effective in treating wounds in participants with Simplex, Recessive Dystrophic, or Junctional non-Herlitz Epidermolysis Bullosa (EB).
- Trial name
- NCT02014376
- Testing
- SD-101 dermal cream (3%), SD-101 Dermal Cream (6%), Vehicle (SD-101 0%)
- Where
- 7 sites in United States
- Volunteers
- 48 people
- Sponsor
- Scioderm, Inc.
Signs and Symptoms
Clinical Trial for Measles - Rubella Combined Vaccine (MRVAC) Produced by POLYVAC (Phase III)
The study is conducted to evaluate the safety and Immunogenicity of Measles-Rubella combined vaccine MRVAC produced by POLYVAC (phase 3) on Vietnamese volunteers and to demonstrate non-inferiority on the immunogenicity of MRVAC…
- Trial name
- NCT03713359
- Testing
- Trial arm (MRVAC), Control arm
- Volunteers
- 756 people, healthy volunteers welcome
- Sponsor
- Center for Research and Production of Vaccines and Biologicals, Vietnam
Controlling Mild to Moderate Bleeding During Surgery
The EVARREST® Pediatric Mild or Moderate Liver and Soft Tissue Bleeding Study
The objective of this study is to evaluate the safety and hemostatic effectiveness of EVARREST as an adjunct to controlling mild to moderate soft hepatic parenchyma or soft tissue bleeding during open hepatic, abdominal, pelvic…
- Trial name
- NCT03255174
- Testing
- EVARREST® Fibrin Sealant Patch
- Where
- 5 sites in United States, United Kingdom
- Volunteers
- 35 people, healthy volunteers welcome
- Sponsor
- Ethicon, Inc.
Vitiligo
Microneedling Combined With Topical Crisaborole 2 % Ointment in Treatment of Vitiligo.
The goal of this clinical trial is to learn if topical crisaborole ointment works to treat vitiligo. It will also learn about the safety of the drug.
- Trial name
- NCT07088276
- Testing
- microneedling with topical crisaborole
- Volunteers
- 20 people
- Sponsor
- Tanta University
Atopic Dermatitis
Efficacy and Safety of a a Biofunctional Textile in the Management of Atopic Dermatitis
Atopic dermatitis (AD) is a chronic inflammatory skin disease characterized by exacerbations and remission of intensely pruritic lesions of variable location.
- Trial name
- 2ndDermisII (NCT01597817)
- Testing
- chitosan coated textile, chitosan free cotton long sleeved t-shirts and pants.
- Where
- Portugal
- Volunteers
- 78 people
- Sponsor
- Universidade do Porto
Full-thickness Skin Defects, Degloving Injuries
RECELL® System Combined With Meshed Autograft for Reduction of Donor Skin Harvesting in Soft Tissue Reconstruction
A prospective randomized within-subject controlled study to compare the clinical performance of conventional autografting with and without the RECELL system on acute non-burn full-thickness skin defects.
- Conditions
- Full-thickness Skin Defects, Degloving Injuries, Crush Injuries, Laceration of Skin
- Trial name
- NCT04091672
- Testing
- Control Intervention (Conventional Autograft), Investigational Intervention (RECELL + more widely meshed autograft)
- Where
- 18 sites in United States
- Volunteers
- 65 people
- Sponsor
- Avita Medical
Angioedema
A Study of Lanadelumab in Teenagers and Adults to Prevent Acute Attacks of Non-histaminergic Angioedema With Normal C1-Inhibitor (C1-INH)
The main aim of this study is to check if repeated subcutaneous (SC) injections of lanadelumab can prevent angioedema attacks in teenagers and adults with non-histaminergic angioedema with normal C1-INH.
- Trial name
- NCT04206605
- Testing
- Lanadelumab
- Where
- 45 sites in United States, Canada and 8 more
- Volunteers
- 77 people
- Sponsor
- Takeda
Hereditary Angioedema
A Study to Evaluate the Safety and Effect of Escalating Doses of CINRYZE
The objectives of the study were: 1. To assess the safety and tolerability of escalating doses of CINRYZE. 2. To assess the effect of an escalating dose algorithm for CINRYZE on hereditary angioedema (HAE) attack rates. 3.
- Trial name
- NCT00914966
- Testing
- C1 inhibitor (human) [C1 INH]
- Where
- 11 sites in United States
- Volunteers
- 20 people
- Sponsor
- Shire
Acne Vulgaris
A Study Comparing Trifarotene Cream 0.005% to AKLIEF® CREAM (US REFERENCE LISTED DRUG), AKLIEF™ CREAM (CANADIAN REFERENCE PRODUCT) in the Treatment of Acne Vulgaris
To demonstrate the efficacy, therapeutic equivalence and safety of Trifarotene Cream 0.005% (Taro Pharmaceuticals U.S.A., Inc.) and US Reference Listed Drug, Canadian Reference Product over the placebo control in the treatment of…
- Trial name
- NCT06733402
- Testing
- Trifarotene Cream 0.005%, AKLIEF® Cream (Trifarotene 0.005%) US REFERENCE LISTED DRUG, AKLIEF® Cream (Trifarotene 50 mcg/g) CANADIAN REFERENCE PRODUCT
- Where
- United States
- Volunteers
- 1,000 people
- Sponsor
- Sun Pharmaceutical Industries, Inc.
Acne Vulgaris
Efficacy and Safety of Clascoterone Cream 1% in Facial Acne Vulgaris
The primary objective of this study is to determine the safety and efficacy of clascoterone cream, 1%, versus the vehicle cream applied twice daily for 12 weeks in subjects with facial acne vulgaris.
- Trial name
- NCT06403501
- Testing
- Clascoterone, Vehicle cream
- Where
- China
- Volunteers
- 692 people
- Sponsor
- Zhejiang Sunshine Mandi Pharmaceutical Co.,Ltd.
Glioblastoma, Brain Tumor
ARISTOCRAT: Blinded Trial of Temozolomide +/- Cannabinoids
ARISTOCRAT is a phase II, multi-centre, double-blind, placebo-controlled, randomised trial to compare the cannabinoid Nabiximols with placebo in patients with recurrent MGMT methylated glioblastoma (GBM) treated with temozolomide…
- Conditions
- Glioblastoma, Brain Tumor, Cannabis, Brain Tumor, Recurrent
- Trial name
- ARISTOCRAT (NCT05629702)
- Testing
- Nabiximols, Temozolomide
- Where
- 17 sites in United Kingdom
- Volunteers
- 122 people
- Sponsor
- University of Birmingham
Acne
Clinical Study to Test the Efficacy and Safety of ACYC to Treat Moderate to Severe Acne
The primary objective of this study is to compare the efficacy and safety and tolerability of ACYC Gel and vehicle in the treatment of subjects with Acne Vulgaris.
- Trial name
- ACYC (NCT01701024)
- Testing
- ACYC, ACYC vehicle
- Where
- 24 sites in United States
- Volunteers
- 498 people
- Sponsor
- Bausch Health Americas, Inc.
Diabetes Mellitus, Type 1
Neurocognitive Performance During Hyperglycemia , and Brain Tissue Integrity in Youth With Type 1 Diabetes and in Healthy
Study population : 90 Participants. 60 with T1DM , and 30 healthy controls. T1DM patients will be recruited by research publication in diabetes mellitus forums. Baseline visit: informed consent signing.
- Trial name
- T1DM (NCT02923323)
- Testing
- MRI including DTI , EEG, CGMS, Neurocognitive tests
- Where
- Israel
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Assaf-Harofeh Medical Center
Acne Vulgaris
A Study of Olumacostat Glasaretil Gel in Subjects With Acne Vulgaris
The objectives of this study are to assess the safety and efficacy of Olumacostat Glasaretil Gel compared to vehicle in patients with acne vulgaris
- Trial name
- NCT03073486
- Testing
- Olumacostat Glasaretil Gel, 5.0%, Olumacostat Glasaretil Gel, Vehicle
- Where
- 46 sites in United States, Australia and 1 more
- Volunteers
- 744 people
- Sponsor
- Dermira, Inc.
Mansonelliasis, Pruritus
Epidemiology and Control of Mansonella Perstans Infection in Uganda
Mansonella perstans (M. perstans) infection is widespread in Uganda. Knowledge about the epidemiology of this infection, and of the morbidity it induces is poor, and no effective treatment is available.
- Conditions
- Mansonelliasis, Pruritus, Lymphoedema, Abdominal Pains
- Trial name
- NCT00215280
- Testing
- ivermectin and albendazole
- Where
- Uganda
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- DBL -Institute for Health Research and Development
Acne Vulgaris
A Study to Evaluate the Safety and Efficacy of CB-03-01 Cream, 1% in Subjects With Facial Acne Vulgaris (26)
The primary objective of this study is to determine the safety and efficacy of CB-03-01 cream, 1%, versus the vehicle cream applied twice daily for 12 weeks in subjects with facial acne vulgaris.
- Trial name
- NCT02608476
- Testing
- CB-03-01 cream, 1%, Vehicle cream
- Where
- 52 sites in United States, Bulgaria and 4 more
- Volunteers
- 732 people
- Sponsor
- Cassiopea SpA
Dermatopolymyositis, Interstitial Lung Disease
Pirfenidone in Progressive Interstitial Lung Disease Associated With Clinically Amyopathic Dermatomyositis
Interstitial lung disease (ILD) is a common complication of dermatomyositis (DM) with prevalence up to 65%, and is considered to be one of the determining factors of prognosis.
- Trial name
- NCT02821689
- Testing
- Pirfenidone
- Where
- China
- Volunteers
- 57 people
- Sponsor
- RenJi Hospital
Acne Vulgaris
A Study Comparing Trifarotene Cream 0.005% to AKLIEF® Cream in the Treatment of Acne Vulgaris
To demonstrate therapeutic equivalence and safety of Trifarotene cream 0.005% (Taro Pharmaceuticals U.S.A., Inc.) and AKLIEF® cream in the treatment of acne vulgaris
- Trial name
- NCT06063473
- Testing
- Trifarotene Cream 0.005%, AKLIEF® Cream (Trifarotene 0.005%, Galderma Laboratories)
- Where
- United States
- Volunteers
- 762 people, healthy volunteers welcome
- Sponsor
- Sun Pharmaceutical Industries, Inc.
Atopic Dermatitis
Indigo Naturalis in Treating Atopic Dermatitis Topically
Atopic dermatitis (AD) is a chronic inflammatory skin disorder that most commonly occurs in children. The aims of this project are: 1. To evaluate the efficacy of indigo naturalis ointment in treating AD topically; 2.
- Trial name
- NCT02669888
- Testing
- Indigo naturalis ointment
- Where
- 3 sites in Taiwan
- Volunteers
- 48 people
- Sponsor
- Chang Gung Memorial Hospital